ArticleThe American journal of pathology1988
Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma.
Article in The American journal of pathology, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.Critical reviews in oncology/hematology · 2017Pooled it
- Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.Investigational new drugs · 2021Trial
- Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.The oncologist · 2018Trial
- Treatment options in platinum-refractory male germ cell cancers: current standards and future directions.Therapeutic advances in medical oncology · 2026Review
- CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas.American journal of hematology · 2026Review
- The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.Cell death & disease · 2024Review
- Clonal diversification and histogenesis of malignant germ cell tumours.Nature communications · 2022Article
- CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.Haematologica · 2021Article
- Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.Molecular pharmaceutics · 2018Article
- Combination cancer immunotherapy and new immunomodulatory targets.Nature reviews. Drug discovery · 2015Review
- Article
- TRA-1-60Journal of stem cell research & therapy · 2013Article
- Targeting CD30 in anaplastic large cell lymphoma.Current hematologic malignancy reports · 2012Review
- Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.Molecular cancer · 2008Article
- Immunohistochemical analysis of neuroendocrine (NE) differentiation in testicular germ cell tumors (GCTs): use of confocal laser scanning microscopy (CLSM) to demonstrate direct NE differentiation from GCTs.Acta histochemica et cytochemica · 2007Article
- Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.Histopathology · 2006Review
- Human embryonal epithelial cells of the developing small intestinal crypts can express the Hodgkin-cell associated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestation.Theoretical biology & medical modelling · 2005Article
- Ber-H2 (CD30) immunohistochemical staining of human fetal tissues.International journal of biological sciences · 2005Article
- Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.The American journal of pathology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ki-1 (CD30) antigen expression has been considered to be restricted to hematopoietic tissues including the recently described anaplastic large cell lymphoma and Reed-Sternberg (RS) cells in Hodgkin's disease. Its presence on some activated lymphocytes in non-neoplastic lymphoid tissues has been used as evidence that such cells might represent the physiologic counterpart of RS cells. In this study expression of CD30 antigen in 117 nonhematopoietic tumors was investigated using monoclonal antibody Ber-H2. The antigen was regularly expressed in frozen section (strongly) and paraffin section (less strongly) by embryonal carcinomas (8 of 10 studied) and the embryonal elements of mixed germ cell tumors (4 of 4), but not in other types of germ cell tumors (0 of 11) or nonhematopoietic tumors (0 of 92). Normal adult, neonatal, and fetal testes were negative for CD30 antigen, as were other fetal tissues and placenta. Ki-1 antibody gives similar results in frozen section. These findings have implications for theories suggesting an origin of RS cells from activated lymphocytes. They are also important for determining the diagnostic significance of CD30 positivity in a tumor of unknown origin, and suggest possible new uses for CD30 antibodies in routine diagnostic immunohistology.
Indexed as
Identifiers
2849300PMC1880812W2241188447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.